Most discontinued anti-tau antibodies (red) targeted tau’s N-terminus. Of the antibodies currently in trials (green), bepranemab and E2814 presented results at CTAD, while JJ-63733657/posdinemab and ...

The ABE achieved over 95% triplex protein knockdown at key gene targets in primary T cells ... The company's SMART platform ...

Scientists at Pohang University of Science and Technology (POSTECH) and ShanghaiTech University have achieved a breakthrough ...

Life Sciences Center (LSC) have discovered a unique way for cells to silence specific genes without cutting DNA. This ...

A pivotal study reveals tactics used by the pathogen Botrytis cinerea to undermine strawberry plant immunity. Researchers ...

Researchers say study offers proof-of-concept that targeting how T cells interact with metabolites in their environment can ...

Cell death-inducing DNA fragmentation factor-like effector C (CIDEC), also known as fat-specific protein 27 (FSP27) in rodents, is a lipid droplet (LD)-associated protein that plays an important role ...

NextCure is going all in on its preclinical B7-H4-directed antibody-drug conjugate (ADC). | NextCure is going all in on its ...

Not everyone responds equally well to treatments for inflammatory bowel disease (IBD). What will work for individual patients involves trial and error during the treatment process.

Claudin 18.2 (CLDN18.2), a tight junction protein, is abnormally activated and overexpressed in several primary ... On the other hand, AK132 also induces potent tumor cell killing through Fc-mediated ...

8: Abstract #217) Nemvaleukin is a novel, engineered fusion protein designed to leverage antitumor effects of the IL-2 pathway ... supporting the hypothesis that nemvaleukin has the potential to ...